Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Blue Jays Pitcher Taillon Blasts MLB’s Lockout Narrative

Blue Jays pitcher Jameson Taillon calls out MLB's CBA spin, claiming the league seeks to drive down salaries for billionaire owners.

Blue Jays Pitcher Taillon Blasts MLB’s Lockout Narrative

Toronto Blue Jays pitcher Jameson Taillon has publicly criticized Major League Baseball's (MLB) perspective on upcoming collective bargaining talks. The veteran ten-year player dismissed the league's recent video statement as "comically bad" and anticipated a contentious round of negotiations. Taillon claims the league's objective is to decrease player wages, thereby enhancing owner profits, rather than striving for a fair game.

This viewpoint underscores a significant rift between the players and the league office, just weeks away from a possible lockout. MLB's contention centers around a video released by Morgan Sword, the executive vice president of player development. The league portrayed proposed changes as a win-win for all parties. Taillon debunked this narrative on November 13, 2026, through a post on X. He alleged that MLB exercises careful control over public statements and visual content to sway fan support ahead of the impending player lockout.

Taillon asserts that these tactics aim to manipulate fan perception prior to the league instituting a lockout. Taillon's core claim underscores the league's intent to slash salaries while enriching billionaires. He explicitly stated that only the owners gain from the proposed changes. The New York Post reported that Taillon remarked the push for these modifications is not about competition within the league.

He labeled the league's public messaging as a mere facade concealing their true financial ambitions. This sentiment resonates with other agents fighting against new constraints on player salaries. Joel Wolfe, an agent for Dodgers ace Yoshinobu Yamamoto, expressed vehement opposition to a salary cap, stating they would accept it "only over our dead bodies."

The league's desire to impose a cap, despite the Brewers' World Series victory with a lower payroll, highlights the disparity in wealth among teams. The league's push for a cap contradicts the evidence that successful teams are not exclusively rich. Taillon's warning about attempts to influence fan support weeks before a lockout carries considerable weight.

He believes the players sense the league is deceiving fans to gain leverage in bargaining. Tensions remain high as the two sides approach the final stages before the new agreement. The Players Association has been vocal about these proposed changes, with Taillon's post indicating growing discontent within the clubhouse.

Written by urgent.news from Yahoo Sports's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at sports.yahoo.com →

More in Finance & Markets

American Express vs. Mastercard: Which Financial Stock Is a Better Buy for 2027?

Amex trades at 17.3x forward earnings while Mastercard commands 32.5x, a valuation gap that raises a real question about which payments giant deserves the premium.

  • American Express reported $72.2 billion revenue with 9.5% growth in latest fiscal year
  • Mastercard generated $32.8 billion revenue with 16.4% growth in latest fiscal year
  • Mastercard offers structural advantage with network-based profit generation

Better Biotech ETF: First Trust's FBT vs. Invesco's PBE

Both biotech ETFs hold about 30 healthcare names, but their index methods and fees differ enough to shape results for investors weighing sector exposure.

  • FBT has lower expense ratio (0.55%) vs. PBE's 0.59%
  • FBT has larger assets under management (70,500) compared to PBE (18,400)
  • PBE utilizes multi-factor quantitative index, FBT tracks NYSE Arca Biotechnology Index

5 Dividend Stocks With High Yields That Are Safer Than You Might Think

A high yield is a sign that investors are worried about a business, but sometimes that concern is overwrought.

  • Pfizer's 5.9% yield is supported by an 85% payout ratio, indicating sustainability.
  • Bristol Myers Squibb's 4% yield has a 55% payout ratio, considered reasonable for pharmaceuticals.
  • Hormel Foods' 5.3% yield is backed by a low debt-to-equity ratio and strong dividend growth history.

More from Saturday 14 November →